Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
An observational study tracking the clinical course of patients with IgA nephropathy.
The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.
Inclusion Criteria:
Exclusion Criteria:
Andreas.schleich@stadtspital.ch+41 44 416 21 55